<DOC>
	<DOCNO>NCT02696707</DOCNO>
	<brief_summary>Several large adjuvant trastuzumab trial demonstrate improved overall survival , participant early stage breast cancer , 33 % decrease risk death . However , retrospective analysis participant outcomes trial demonstrate increase risk cardiotoxicity ( i.e damage heart ) small number patient ( 4-8 % ) . At time , investigator unable predict participant increase risk cardiac-related treatment complication . Currently patient receive regular cardiac image throughout one year trastuzumab treatment . At time , optimal monitoring schedule trastuzumab-related cardiotoxicity remain unknown , several publish consensus guideline currently use `` standard care .</brief_summary>
	<brief_title>An Integrated Consent Model Study Compare Two Standard Care Schedules Monitoring Cardiac Function Patients Receiving Trastuzumab Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm early stage HER2positive breast cancer Planned trastuzumab therapy early stage breast cancer ≥18 year age Able provide verbal consent Normal LVEF ( &gt; 53 % ) trastuzumab therapy • Contraindication transthoracic echocardiography MUGA</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cardiac toxicity</keyword>
</DOC>